RecruitingPhase 1

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

A Phase 1, Open-Label Study to Evaluate the Effect of Eloralintide on the Pharmacokinetics of the Combined Oral Contraceptive Levonorgestrel-Ethinyl Estradiol in Female Participants With Obesity or Overweight

Lead sponsor

Eli Lilly and Company

Asset

Eloralintide

Subcutaneous · Amylin analog

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

•BMI 27-35•Female

Primary endpoints

•AUC•PK: Maximum Concentration (Cmax) of Ethinyl Estradiol and Levonorgestrel•PK: Time to Maximum Concentration (Tmax) of Ethinyl Estradiol and Levonorgestrel

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07808060

Org study ID27897

Secondary IDJ3R-MC-YDAUEli Lilly and Company

Timeline

Milestones

Study first posted2026-09-08actual

Study start2026-09-15actual

Last update posted2026-10-08actual

Primary completion2027-06estimated (month precision)

Study completion2027-06estimated (month precision)

Assets

Investigational agents

Eloralintide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age60 Years

SexFemale

Healthy volunteersAccepted

Inclusion criteria

•Are individuals AFAB who are individuals of childbearing potential using non-hormonal methods of contraception, or individuals not of childbearing potential.

•Have safety laboratory test results within normal reference range for the population or investigative site.

•Have a body mass index (BMI) within the range of 27.0 to 35.0 kilograms per square meter (kg/m²), inclusive.

•Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.

Exclusion criteria

•Have a history or presence of contraindications to the Combined Oral Contraceptive (COC) tablet including thrombosis and the history of any thromboembolic disease, recurrent jaundice, acute or chronic liver disease, hormonally-induced migraines, undiagnosed vaginal bleeding, significant hyperlipidemia, and mammary, endometrial, or hepatic carcinoma (known or suspected).

•Have known risks of arterial or venous thrombotic diseases.

•Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.

•Have a known clinically significant gastric emptying abnormality; a GI disorder that impacts GI absorption or gastric emptying; or have undergone weight loss surgery; or have had endoscopic and/or device-based therapy for obesity or device removal within the last 6 months.

•Have a history of breast, uterine or ovarian cancer any time or have any malignancy within the past 5 years with the exceptions of basal cell or squamous epithelial carcinomas of the skin, or cervical carcinoma in situ.

•Have received drugs that reduce GI motility within 1 month prior to screening.

•Have received oral contraceptives within 3 months, implanted contraceptives within 6 months, injectable contraceptives within 12 months, or topical controlled delivery contraceptives (patch) or hormonal intrauterine device within 3 months prior to the study or plan to use during the study.

•Have an estimated glomerular filtration rate (eGFR), using the Chronic Kidney Disease Epidemiology Collaboration equation (2021), less than 60.0 milliliter per minute per 1.73 square meters (mL/Minute/1.73m²).

•Are pregnant or intend to become pregnant or to breastfeed during the study.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

3 endpoints

Primary/protocol endpoint

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Ethinyl Estradiol and Levonorgestrel

Time frame:Baseline through Day 128

concentration, descriptive

Primary/protocol endpoint

PK: Maximum Concentration (Cmax) of Ethinyl Estradiol and Levonorgestrel

Time frame:Baseline through Day 128

concentration, descriptive

Primary/protocol endpoint

PK: Time to Maximum Concentration (Tmax) of Ethinyl Estradiol and Levonorgestrel

Time frame:Baseline through Day 128

time to event, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.